|
November 7, 2023
|
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
|
November 6, 2023
|
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
|
|
|
November 1, 2023
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
October 18, 2023
|
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
|
|
September 27, 2023
|
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
|
|
|
August 29, 2023
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
August 8, 2023
|
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
|
|
|
July 13, 2023
|
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
|
|
|
July 13, 2023
|
Caribou Biosciences Announces Proposed Public Offering of Common Stock
|
|
|
July 13, 2023
|
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
|
|
